You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-lymphoma agents

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Relapsed/Refractory Classical Hodgkins Lymphoma
  • Duarte, California
  • +33 more
Jan 5, 2023

B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Loncastuximab Tesirine
  • +4 more
  • Pembroke Pines, Florida
  • +19 more
Jul 22, 2022

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +86 more
Jan 23, 2023

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Idelalisib,

Completed
Has Results
  • Indolent Non-Hodgkin's Lymphoma
  • +2 more
  • Huntsville, Alabama
  • +10 more
Feb 22, 2021

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

Advanced Solid Tumor Trial (SHR-A1921;)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Feb 28, 2023

Stroke, Medication Adherence Trial in Kumasi (Polycap)

Not yet recruiting
  • Stroke
  • Medication Adherence
  • Kumasi, Ghana
    Kwame Nkrumah Institute of Science & Technology
Jul 19, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Uncomplicated Plasmodium Falciparum Malaria Trial (INE963, KAE609, SoC (Coartem))

Not yet recruiting
  • Uncomplicated Plasmodium Falciparum Malaria
  • (no location specified)
Feb 17, 2023

Non-Hodgkin Lymphoma Trial in Worldwide (Epcoritamab, Lenalidomide, Ibrutinib)

Recruiting
  • Non-Hodgkin Lymphoma
  • Tucson, Arizona
  • +81 more
Jan 25, 2023

Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and

Not yet recruiting
  • Disability or Chronic Disease Leading to Disablement
  • +2 more
  • Surgical flap and anti-bacterial agents
  • Garches, France
    Department of Physical Medicine and Rehabilitation, Raymond Poin
Feb 1, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New

Recruiting
  • Mantle-cell Lymphoma
  • B Cell Chronic Lymphocytic Leukemia
    • Monza, MB, Italy
      Andrea Aroldi
    May 24, 2023

    Solid Tumor Trial in Chuo-ku (ROSE12, Atezolizumab)

    Recruiting
    • Solid Tumor
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital
    Jun 14, 2023

    Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Low-Dose Decitabine plus anti-PD-1
    • Beijing, Beijing, China
      ChinaPLAGH
    Apr 18, 2023

    T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)

    Withdrawn
    • T-cell Acute Lymphoblastic Leukemia
    • T-lymphoblastic Lymphoma
    • Target CD7 CAR-T cells
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force of People's Libe
    Nov 23, 2022

    NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • (no location specified)
    Sep 6, 2023

    Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

    Recruiting
    • Acute T-lymphoblastic Leukemia
    • Acute T-lymphoblastic Lymphoma
    • CAR-T Cell Infusion
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    Cancer, Tumor, Solid, Malignant Tumor Trial (OR502, Cemiplimab)

    Not yet recruiting
    • Cancer
    • +6 more
    • (no location specified)
    Oct 16, 2023

    Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Trial in

    Recruiting
    • Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
    • Columbus, Ohio
    • +9 more
    Aug 1, 2022

    Atherosclerosis, Adherence, Medication, Tolerance Trial in Kumasi (Polycap)

    Completed
    • Atherosclerosis
    • +2 more
    • Kumasi, Ghana
      Kwame Nkrumah University of Science & Technology
    Sep 29, 2022

    Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

    Not yet recruiting
    • Blastoid Variant Mantle Cell Lymphoma
    • +2 more
    • Biopsy
    • +8 more
    • Duarte, California
      City of Hope Medical Center
    May 15, 2023